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Abstract—Treatment of heart failure with preserved ejection
fraction (HFpEF) remains a major unmet medical need. An
implantable valveless pulsatile pumpwitha single cannula—the
CoPulse pump—may provide beneficial hemodynamic support
for select HFpEF patients when connected to the failing
ventricle. We aimed to demonstrate hemodynamic efficacy
and hemocompatible design feasibility for this novel assist
device. The hemodynamic effect of the pump was investigated
with an in vitro circulatory mock loop and an ex vivo isolated
porcine heart model. The hydraulic design was optimized using
computational fluiddynamics (CFD), andvalidatedby4D-flow
magnetic resonance imaging (MRI). The pump reduced left
atrial pressure (> 27%) and increased cardiac output (> 14%)
in vitro. Ex vivo experiments revealed elevated total stroke
volume at increased end-systolic volume during pump support.
Asymmetric cannula positioning indicated superior washout,
decreased stagnation (8.06 mm2 vs. 31.42 mm2), and marginal
blood trauma potential withmoderate shear stresses (< 24 Pa)
in silico. Good agreement in flow velocities was evident among
CFD and 4D-flow MRI data (r > 0.76). The CoPulse pump
proved hemodynamically effective. Hemocompatibility metrics
were comparable to those of a previously reported, typical
pulsatile pump with two cannulae. The encouraging in vitro,
ex vivo, and hemocompatibility results substantiate further
development of the CoPulse pump.
Keywords—CFD, 4D-flow MRI, Single cannula, Isolated
porcine heart model, In vitro, Ex vivo, In silico, Washout,




HFrEF Heart failure with reduced ejection
fraction
HFmrEF Heart failure with mid-range ejection
fraction
HFpEF Heart failure with preserved ejection
fraction
LAP Left atrial pressure
MCS Mechanical circulatory support
LV Left ventricle
SV Stroke volume
VAD Ventricular assist device
LVP Left ventricular pressure
LVR Left ventricular reservoir
AoP Aortic pressure
PAP Pulmonary artery pressure
CO Cardiac output
LVV Left ventricular volume
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HR Mean heart rate
SWLV Left ventricular stroke work
PELV Left ventricular potential energy
PVALV Left ventricular pressure-volume area
ESPVR End-systolic pressure volume relationship
CFD Computational fluid dynamics
MRI Magnetic resonance imaging
ECG Electrocardiography
RMSE Root mean square error
PIV Particle image velocimetry
pVAD Pulsatile ventricular assist device
INTRODUCTION
Heart failure (HF) can be classified into three cat-
egories based on the ejection fraction (EF): heart fail-
ure with reduced (HFrEF), mid-range (HFmrEF), and
preserved ejection fraction (HFpEF). While HFrEF
has attracted most of the scientific and clinical
research, difficulties of diagnosing the typical mani-
festations of HFpEF (e.g. impaired diastolic ventricu-
lar function) have left this phenotype less clearly
understood.17,23
HFpEF accounts for roughly half of all heart failure
cases24 and constitutes a patient population which is
projected to grow.23 Furthermore, HFpEF exhibits
similar incidence of mortality and morbidity as
HFrEF.2,23,24,26 An unaddressed clinical need for
effective treatment of HFpEF exists as there are no
clinically available options that significantly improve
outcomes: Pharmacologic studies have shown that
typical heart failure medications are ineffective in
HFpEF patients.4,20 Further, intra-arterial shunt de-
vices, specifically aiming to reduce the commonly ele-
vated left atrial pressure (LAP) among HFpEF
patients, have not yet shown significant efficacy.27
Mechanical circulatory support (MCS) provides an
alternative means for reducing LAP. MCS has been
studied in patients with hypertrophic and restrictive
cardiomyopathies with low ejection fraction,25 but has
not yet been clinically evaluated in HFpEF patients.
However, numerical studies have shown that MCS,
through either ventricular or atrial cannulation, could
be an effective treatment strategy for certain pheno-
types of HFpEF.5,22 Yet, contemporary MCS systems
are accompanied by severe adverse events related to
device hemocompatibility. Thromboembolic and
bleeding events are stirred by the non-physiologic flow
within the device—high shear rates and prolonged
residence times of blood particles lead to blood trauma
and thrombus formation.3 In pulsatile pumps, the
valvular regions are an additional source for thrombus
formation.14
In a recent numerical study, we showed the potential
of using a 30 mL volume displacement pump with a
single valveless cannula directly connected to the dis-
eased ventricle to improve the hemodynamic state of
HFpEF patients.11 By synchronously filling and emp-
tying the pump with the diseased left ventricle (LV),
the pump could provide additional stroke volume (SV)
by capitalizing on the stiff systolic properties of the LV
during ejection. Additionally, the end-systolic volume
could be increased, thereby potentially mitigating the
risk of suction events. This novel concept of an assist
device for HFpEF—henceforth denoted as CoPulse
pump—may additionally address some of the hemo-
compatible design weaknesses associated with con-
ventional MCS: (1) pulsatile devices have been
associated with lower shear rates than rotary blood
pumps,7 (2) the valveless design eliminates the main
location of blood clots for pulsatile devices.14
The present study aimed at continuing the devel-
opment of the CoPulse pump to a functioning proto-
type. In accordance with the state-of-the-art
development practice for ventricular assist devices
(VADs), this involved fabrication of the physical pump
system, validation of earlier in silico hemodynamic
findings11 in vitro, further evaluation of the CoPulse
efficacy ex vivo, and preliminary optimization of the
pump’s hydraulic characteristics using computational
fluid dynamics (CFD) and 4D-flow magnetic reso-
nance imaging (MRI).
MATERIALS AND METHODS
The CoPulse Pump—Prototype Fabrication
and Actuation
Functional prototypes of the CoPulse pump were
fabricated to be used for all experimental investiga-
tions and according to the symmetric (Figs. 1a and 1b)
and the asymmetric (Figs. 1c and 1d) designs that were
hydraulically optimized using CFD (Fig. 4). The pump
housing was 3D-printed with a Formlabs Form 2 using
Clear Resin (Formlabs, Somerville, MA, USA) with
minimal wall thickness of 2.5 mm. The membrane (arc
diameter: 53 mm, amplitude: 12.6 mm) was acquired





Berlin, Germany) and divided the pump into a pneu-
matic and a blood chamber to displace an approximate
30 mL stroke volume (Supplementary Figure 1). A
single valveless cannula (inner diameter: 15 mm,
length: 25 mm) provided connection of the blood
chamber to the LV apex (Fig. 1e).
A pneumatic line connected the pneumatic chamber
of the pump to a pneumatic system, which transferred
positive and vacuum pressures to drive the recipro-
cating membrane movement. The pneumatic system
(Fig. 2) consisted of an air compressor (KNF Neu-
berger PM21308-023.1.2, Freiburg, Germany), two air
tanks—one for positive pressure and another for vac-
uum pressure, relief valves (Niezgodka GmbH 91-
2508-4 and 1831, Hamburg, Germany), and a 5/3-way
solenoid control valve (Festo MPYe-5-1/4-010-B,
Esslingen am Neckar, Germany). To synchronize
ejection and filling of the CoPulse pump with the LV
cardiac cycle, a control system was developed that
utilized the left ventricular pressure (LVP) as an input
signal; the control system and pump phasing are de-
scribed in detail in Supplementary Figure 2. The con-
trol system was implemented in MATLAB Simulink
(The MathWorks, Natick, MA, USA) and deployed
onto a dSPACE MicroLAB Box (dSPACE GmBH,
Paderborn, Germany).
Validation of Hemodynamic Efficacy
In Vitro Analysis in a Hybrid Mock Circulation
The pump prototype was tested in vitro in a hybrid
mock circulatory loop to evaluate pump and control
system functionality, and to validate hemodynamic
findings from previous in silico studies11 (Fig. 2a).
Unlike the in silico studies, the hybrid mock circulatory
loop provided a platform to test the functionality of
the CoPulse pump and to model the cardiovascular
system’s response to a physical prototype of the pump.
The loop consisted of three main components: (1) the
hydraulic loop, (2) the pneumatic actuation system,
FIGURE 1. (a) Top-view photo of the symmetric CoPulse prototype, (b) Side-view photo of the symmetric CoPulse prototype, (c)
Top-view photo of the asymmetric CoPulse prototype, (d) Side-view photo of the asymmetric CoPulse prototype, (e) Photo of the
CoPulse pump implanted into the left ventricle of the ex vivo isolated porcine heart. (a)–(d) label the design variables used for
geometric pump optimization and are denoted by h (pump chamber height), d (cannula diameter), w (cannula offset distance), and
h (cannula orientation). The geometric range of the respective design variables is reported in Supplementary Table 1. (a)–(d) also
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and (3) the software including the control unit running
a cardiovascular numerical model11 as well as the
control algorithm for the CoPulse pump. The hy-
draulic loop consisted of the LV reservoir (LVR), the
CoPulse pump, and a cannula that connected them to
allow for clamp-on flow measurement (Sonoflow
CO.55, Sonotec GmbH, Halle, Germany; measure-
ment error: ± .024 L/min for flows 0–1.2 L/min
and ± 2% for flows > 1.2 L/min). The loop was filled
with a glycerol/water mixture (3.0–3.5 mPa s). Mea-
sured pump flow (QPump) (example waveform shown in
Supplementary Figure 2B) was passed to the numerical
model to simulate the cardiovascular system’s response
to CoPulse support. Briefly, the numerical model was
implemented as a lumped parameter model of the
cardiovascular system as presented by Granegger
et al.11 Model parameters were adapted to achieve
typical HFpEF conditions as previously reported.5,11,22
The resultant LVP output from the numerical model
was passed as the setpoint to a PID control system,
which in turn actuated a separate solenoid control
valve to control the pressure in the LVR. Thus, the
LVP was controlled to simulate the modeled LVP and
was, analogous to pneumatic and hydraulic pump
pressures, measured using an APT300 pressure trans-
ducer (Harvard Apparatus, Holliston, MA, USA;
measurement error: ± 1.7%). All other reported flows
and pressures were outputs of the numerical model11:
LAP, cardiac output (CO), aortic pressure (AoP),
pulmonary artery pressure (PAP), and left ventricular
volume (LVV).
The hemodynamic effect of the pump was evaluated
in four typical end-stage HFpEF phenotypes, each of
which were implemented separately as part of the
numerical model (Supplementary Figure 3): (I)
Genetically inherited hypertrophic cardiomyopathy,
(II) Infiltrative cardiomyopathy with restrictive physi-
ology, (III) Nonhypertrophic cardiomyopathy, (IV)
Normal ejection fraction with comorbidities (i.e
hypertension, coronary artery disease) and hypertro-
phy.5,11 The hybrid model outputs for LVP, LVV,
AoP, PAP, LAP, and CO were used to validate pre-
vious in silico results.11
FIGURE 2. Schematic diagrams of (a) the in vitro hybrid mock circulatory loop system, (b) the ex vivo isolated beating heart
setup, (c) the 4D-flow MRI setup. Air tank 1 for positive pressure (AT1 Pos); air tank 2 for vacuum pressure (AT2 Vac); regulator
valve (RegV); solenoid valve (SoV); left ventricular reservoir (LVR); aortic reservoir (AoR); preload reservoir (PR); venous reservoir






Ex Vivo Isolated Heart Experiments
Following the in vitro study, the pump prototype
was tested ex vivo in an isolated beating porcine heart
setup to investigate the interaction between the cardiac
mechanics of a functional left ventricle and the pump,
as well as to further evaluate the hemodynamic efficacy
of the pump (Figs. 1e and 2b). The previously de-
scribed isolated heart setup10,12 consisted of a pressure-
controlled preload reservoir (PR), an aortic reservoir
(AoR), a venous reservoir (VR), an oxygenator/heat
exchanger, and a controllable roller pump to set the
preload. An adjustable hosecock clamp on the systemic
return line between the AoR and the VR allowed for
manual control of the afterload resistance. AoP, LAP,
PAP, and pneumatic pump pressure were measured
using APT300 pressure transducers. Aortic (AoF) and
coronary flow (CoF) were recorded using Sonoflow
CO.55 clamp-on flow sensors. LVP and LVV were
measured using a Ventri-Cath 507 pressure-volume
(PV) Loop Catheter (ADInstruments, Sydney, Aus-
tralia).
All experiments were approved by the Ethics
Committee (Approval No. 219/16) of the Canton of
Zurich. The hearts (n = 4) were explanted and con-
nected to the setup as previously described.10,12 In 3
hearts the pump was implanted successfully and
maintained functionality. Constant LAP (n = 3) and
constant CO (n = 3) measurements were recorded
with each measurement of a single type being con-
ducted within a separate heart. Two sets of reliable
LVV data were recorded for both constant LAP and
constant CO experiments.
Following completion of each experiment, the
heart’s end-diastolic pressure-volume relationship
(EDPVR) was determined by inflating a balloon with
water inside the LV while measuring both the pressure
and volume. LVV conductance catheter measurements
were calibrated using the measured stroke volume to
calibrate the slope factor and the EDPVR to calibrate
the parallel conductance.
Data Analysis for In Vitro and Ex Vivo Hemodynamic
Evaluation
All data was recorded by the dSPACE MicroLab
Box at 200 Hz and analyzed using MATLAB software.
All mean hemodynamic parameter values were calcu-
lated on a beat-to-beat basis, averaged over 10 second
epochs and presented as mean ± standard deviation.
To evaluate the effect of the pump on the LV stroke
volume, the stroke volumes of the LV (SVLVÞ, pump
(SVPump), and LV + pump ðSVLVþPumpÞ were calcu-
lated as:
SVLV ¼ EDV ESV













where EDV is the end-diastolic volume (mL), ESV the
end-systolic volume (mL), and HR the mean heart rate
(bpm). The volume of the pump was derived as the
cumulative numerical time integral of the pump flow.
Then the stroke volume was calculated as the differ-
ence between the maximal and minimal pump volumes
over a single pump cycle with t0 denoting the start of
ejection and tend the end of filling.
To evaluate how cardiac energetics are affected by
the CoPulse pump, the work performed by the pump
was calculated as the area enclosed by the pump fluid
PV loop. Furthermore, the left ventricular stroke work
(SWLV), potential energy (PELV), and the pressure-
volume area (PVALV) were calculated assuming a zero
pressure ventricular volume V0 of 0 mL, a linear end-
systolic pressure-volume relationship (ESPVR), and
the measured EDPVR. Pump volumetric and work
efficiency were calculated as:
PumpVolumetric Efficiency
¼




SWLV;CoPulse Support þWPump;CoPulse Support  SWLV;Baseline
WPump;CoPulse Support
Investigation of Fluid Dynamics and Related
Hemocompatibility
Numerical Simulations
CFD was employed for numerical flow inspection,
hemocompatibility characterization and hydraulic de-
sign optimization of the pump. The fluid volume was
discretized with the CFD package Star CCM+ (Sie-
mens, Munich, Germany), resulting in an unstructured
core volume mesh composed of approximately 1.5
million polyhedral cells. Controlled local mesh refine-
ment was combined with five prism layers at the walls
to better resolve the high gradients in boundary layers.
While a wall boundary with no-slip condition was
stipulated for the inner blood chamber and cannula
surface, a pressure outlet boundary condition was set
at the cannula inlet. The membrane was implemented
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profile. To this end, the membrane contour (AExcor)
was extracted from a front view photograph of an in-
flated 30 mL Excor pump diaphragm using a tenth







where rExcor denotes the radial distance on the mem-
brane (m), p the polynomial coefficients (m 1lð Þ) and l
the polynomial order (–).
Time-periodic membrane motion was programmed
by superimposing this membrane contour with a
sinusoidal time evolution of heart rate 75 bpm and 1:1
diastolic/systolic support mode:




where t denotes the time (s) and f the frequency (Hz).
Mesh morphing was employed for dynamic mesh
adaptation to accommodate the membrane deflection.
The numerical solution of the Navier–Stokes equa-
tions was derived based on the Finite Volume Method,
while turbulence was accounted for by implementing
the Reynolds Averaged Navier–Stokes k–x Shear
Stress Transport turbulence model.21 The time step
was set to 1023 s while all residuals were required to
decay below 1024 to ensure convergence.13,18
Blood was modelled as Newtonian fluid with con-
stant density q = 1050.0 kg m23 and dynamic vis-
cosity l = 3.5 mPa s.1 Blood stagnation was assumed
if flow velocities fell below 0.02 m s21. To evaluate
chamber washout, a passive scalar transport equation
was implemented and, at the cannula inlet, a Dirichlet
boundary condition was imposed on the passive scalar
representing the dye concentration J (–)18:
Dye Washout : # ¼
1 if c ¼ 1
0 else

where c is the cycle number. The dye was injected
during one cycle, while subsequently being ejected over
consecutive cycles. The duration t95 (s) served as a




Further, a continuous arbitrary Lagrangian–Eule-
rian formulation of residence time was implemented
and the time RT1 (s) employed as a metric for average
blood residence time as proposed by Long et al.18:







H xð Þs x; tð ÞdXdT







H xð ÞdXdT and
H xð Þ ¼
1 if x 2 V
0 else

where x denotes the spatial coordinates (m), H(x) the
Heaviside function (–), T the cycle period (s), X = V
the instantaneous blood chamber volume including the
cannula (mL), and s the residence time distribution (s).
An objective function was defined to account for
washout performance (t95, RT1) as previously intro-
duced in a shape optimization study of a pulsatile
ventricular assist device (pVAD),19 while additionally
considering peak shear stresses and blood stagnation.
Iterative hydraulic design optimization was performed
to converge upon an appropriate pump configuration.
Four design variables were studied including the pump
chamber height h (m), the cannula diameter d (m), the
cannula offset distance w (m) and the cannula orien-
tation h () (Figs. 1a–1d), each of which modified
within a specified geometric range (Supplementary
Table 1). Each design iteration was sequentially
implemented and studied while evaluating the objec-
tive function to be minimized. This process converged
towards a symmetric and an asymmetric design (Fig-
s. 1a–1d) and the comparison thereof is described be-
low.
Validation of Numerical Simulations Using 4D-Flow
MRI
To validate the numerical simulations, the manu-
factured symmetric and asymmetric prototypes (Fig-
s. 1a–1d) were assessed using 4D-flow MRI performed
on a 1.5T GE Discovery MR450 scanner (GE, Mil-
waukee, USA). The CoPulse pneumatic and control
systems were housed outside of the scanner room
(Fig. 2c). An 8 mm diameter airline was passed
through the penetration panel to drive the pump
within the scanner bore. The pump was submerged in a
static water bath and connected via inflow cannula to a
cylinder (diameter: 120 mm, height: 290 mm) filled
with a glycerol/water mixture mimicking blood vis-
cosity (3.0 mPa s). The cylinder acted as an open
reservoir, while driving pressures for the pump were
adapted to achieve physiologic filling/ejection timings
and waveforms analog to previous in silico and in vitro
results.11
A replica ECG signal was passed from the pump
control unit to the scanner ECG input to allow MRI
cardiac gating as per a typical ECG gated 4D-flow
examination.8 A 4-point encoding 4D-flow sequence
was acquired using a 32-channel phased-array cardiac
coil covering the pump and surrounding water bath. A





on earlier CFD simulations and confirmed during
preliminary testing to avoid phase aliasing. For all
acquisitions, data were acquired in a coronal orienta-
tion with an acquired isotropic resolution of 2.0 mm3,
which was reconstructed to an inplane voxel size of 1.4
9 1.4 mm and slice thickness of 2.0 mm. Other 4D-
flow MRI acquisition parameters were: echo time
(2.46 ms), repetition time (4.42 ms), flip angle (7),
number of phases (25), and temporal resolution
(32 ms). Signal averaging (NEX) of 4 was used. In
addition to the 4D-flow sequence, a high temporal
(20 ms) and spatial (0.94 9 0.94 mm inplane, 3.0 mm
slice thickness) resolution Fiesta Cine sequence was
acquired providing clear resolution of the pump
membrane movement.
Static data from the water bath was manually seg-
mented and used to correct for background phase
artifacts by fitting a third order polynomial function.28
Post-processing of MRI data was performed using
previously validated in-house software and Paraview
(Kitware Inc., NY, USA).6
To produce CFD simulations comparable to the
dynamics of the 4D-flow MRI data for validation, the
sinusoidal membrane timing in the numerical setup
was replaced by the actual diaphragm timing extrap-
olated from the MR scan. Validation was performed
by comparing flow and velocity profiles from CFD and
4D-flow MRI data at probe points within the cannula
and near the membrane insertion.
RESULTS
Hemodynamic Evaluation
In Vitro Evaluation in a Hybrid Mock Circulation
and Validation of In Silico Results
The mean hemodynamic values at each baseline and
CoPulse support condition for the four different
HFpEF phenotypes are shown in Table 1.
Baseline unsupported conditions were indicative of
typical HFpEF hemodynamics, such as elevated LAP
(> 19 mmHg) and high PAP (> 28 mmHg). CoPulse
pump support decreased mean LAP (27–34%) and
mean PAP (16–17%) while increasing mean AoP (13–
20%) and mean CO (14–31%). With a SVPump of 32.4–
33.2 mL, the SVLV was reduced by 15–18 mL (18–
39%), but the overall SVLVþPump increased by 10–
13 mL (14–30%). This equated to a 31–41% pump
volumetric efficiency and 68–85% pump work effi-
ciency. The lowest efficiencies were observed for the
HFpEF II phenotype.
By filling synchronously during LV filling and
ejecting during LV ejection, the pump performs 0.38–
0.45 J of hydraulic work as it unloads the LV, and
consequently, the LA during diastole, and ejects vol-
ume into the LV and systemic circulation during sys-
tole. This resulted in a reduction in SWLV of .06–.12 J
(7–31%) and an increase in PELV of .08–.10 J (20–
49%) for an overall small change in PVALV of .02–
.04 J (3–5%).
Comparing mean hemodynamic values to those
obtained from previously conducted in silico results,11
errors for AoP, LAP, and PAP were less than
1.3 mmHg (< 3.98%), and errors for CO were less
than .081L min21 (< 1.33%). PV loops of the LV
from simulations and the in vitro experiments are dis-
played in Supplementary Figure 3 and show a high
level of agreement (RMSE < 2.8 mmHg between
LVPsimulation and LVPin vitro, RMSE < 2.0 mL
between LVVsimulation and LVVin vitro).
Ex Vivo Evaluation in Isolated Heart Experiments
In constant LAP experiments, preload was main-
tained (LAP changed 0.3 ± 2.2%) at a constant heart
rate (HR changed 1.2 ± 3.7%) between baseline and
CoPulse support conditions (Fig. 3c). All preload
experiments exhibited increased AoP (33 ± 15%) and
CO (21 ± 9.3%) with CoPulse support. Additionally,
CoPulse support decreased SWLV (35 ± 22%), and
increased PELV (65 ± 1.9%) for an overall increase in
PVALV (19 ± 3.7%). The minimum ESV was
increased from 17.6 mL to 22.7 mL during CoPulse
support (Fig. 3a).
In constant CO experiments, CO was maintained
(CO changed 3.1 ± 0.5%) at a constant heart rate (HR
changed 0.3 ± 0.5%) between baseline and CoPulse
support conditions (Fig. 3c). All CO experiments
exhibited decreased LAP (58 ± 14%) with CoPulse
support. Additionally, CoPulse support decreased
SWLV (75 ± 14%) with greater magnitude than it
increased PELV (10 ± 9.8%) for an overall decrease in
PVALV of 36 ± 7.4%. The minimum ESV increased




Flow distribution was analyzed on a horizontal
analysis plane (Fig. 4a). The flow field in the outermost
region of the symmetric CoPulse configuration
(Fig. 4b, left) revealed velocity magnitudes below the
stagnation threshold throughout mid-diastole (tMD),
end-diastole (tED), and end-systole (tES). In contrast,
the asymmetric cannula configuration (w = 18 mm,
h = 60) introduced substantial azimuthal, unidirec-
tional flow (> 0.02 m s21) that perfused the pump
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TABLE 1. Mean hemodynamic, pump, and energetic values from in vitro hybrid mock loop HFpEF phenotype experiments.
Hemodynamic
parameter


















AoPmean (mmHg) 81 101 20 (25%) 75 90 15 (20%) 76 91 15 (20%) 93 105 12 (13%)
LAPmean (mmHg) 20 13 2 8 (2 27%) 19 13 2 7 (2 34%) 24 17 2 7 (2 28%) 26 18 2 8 (2 30%)
PAPmean (mmHg) 30 25 2 5 (2 16%) 28 24 2 4 (2 16%) 31 26 2 5 (2 16%) 36 30 2 6 (2 17%)
COmean (L/min) 3.2 4.2 1 (31%) 4.1 5.0 1 (22%) 4.1 5.0 1 (22%) 6.2 7.1 1 (14%)
Heart Rate (bpm) 75 75 0 (0%) 90 90 0 (0%) 70 70 0 (0%) 72 72 0 (0%)
SVLV (mL) 44.1 28.9 2 15
(2 35%)
46.3 28.1 2 18
(2 39%)
59.8 44.4 2 15
(2 26%)
87.0 71.5 2 15
(2 18%)
SVLV+Pump (mL) 44.1 57.3 13 (30%) 46.3 56.6 10 (22%) 59.8 73.1 13 (22%) 87.0 99.4 12 (14%)
SVPump (mL) – 32.4 – – 32.7 – – 33.0 – – 33.2 –
SWLV (J) 0.40 0.33 2 .07
(2 18%)
0.39 0.27 2 .12
(2 31%)
0.50 0.44 2 .06
(2 12%)
0.97 0.90 2 .07 (2 7%)
PELV (J) 0.18 0.27 .09 (49%) 0.22 0.32 .10 (46%) 0.23 0.32 .10 (43%) 0.40 0.48 .08 (20%)
PVALV (J) 0.59 0.60 .02 (3%) 0.61 0.59 2 .02 (2 3%) 0.73 0.76 .04 (5%) 1.37 1.37 .01 (0.6%)
WPump (J) – 0.41 – – 0.38 – – 0.39 – – 0.45 –
Pump volumetric
efficiency
– 41% – – 31% – – 40% – – 37% –
Pump work effi-
ciency
– 83% – – 68% – – 85% – – 85% –
Mean parameter values are shown at baseline and with CoPulse pump support for each HFpEF phenotype, along with the absolute changes and % changes in parentheses of the
hemodynamic parameter values from baseline to CoPulse pump support. HFpEF I denotes the phenotype of genetically inherited hypertrophic cardiomyopathy, HFpEF II the state of
infiltrative cardiomyopathy with restrictive physiology, HFpEF III the condition of nonhypertrophic cardiomyopathy without significant cardiac comorbidities, while HFpEF IV refers to patients







































(Fig. 4b, right). Consequently, areas of prolonged
blood stagnation exceeding 5 s in a simulation of six
consecutive pump cycles were significantly reduced by
74.35% (8.06 vs. 31.42 mm2) in the asymmetric design
as compared to its symmetric counterpart (Fig. 4c).
The time evolution of dye washout in both pump
designs is illustrated in Fig. 5. After a first pump cycle
(t = 0–0.8 s), less dye was remaining in the symmetric
configuration (40.15%) as compared to its asymmetric
counterpart (47.79%). However, in the subsequent
cycles, similar washout characteristics with comparable
values in t95 (2.67 s vs. 2.66 s) and RT1 (0.99 s vs.
0.95 s) were observed in both designs of the CoPulse
pump.
In both configurations, peak wall shear stresses oc-
curred during ejection at the site where the cannula
attaches to the pump chamber (symmetric design:
15.65 Pa, asymmetric design: 23.56 Pa). Peak shear
stresses on the membrane occurred during filling at the
site of the entering jet (symmetric design: 10.80 Pa,
asymmetric design: 18.11 Pa).
Validation of Numerical Simulations
Flow and velocity profiles of CFD and 4D-flow
MRI data are depicted in Fig. 6. The profiles illustrate
the time course of a single pump cycle including dias-
tole (t = 0–0.25 s), end-diastolic period (t = 0.25–
FIGURE 3. Representative PV loops at baseline and pump support conditions during ex vivo isolated heart constant LAP and
constant CO experiments are shown in (a) and (b), respectively. When LAP was held constant, ESV was noticeably increased.
When CO was held constant, the ESV was not noticeably affected. Mean hemodynamic values at baseline and pump support
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FIGURE 4. (a) Location of the horizontal analysis plane in the symmetric and the asymmetric prototype. To provide visibility of
the Excor membrane and the horizontal analysis plane, the housing of the blood chamber is lifted. (b) Velocity fields in horizontal
analysis plane for the symmetric and asymmetric design of the CoPulse pump at the time instants mid-diastole (tMD), end-diastole






0.36 s), systole (t = 0.36–0.59 s), and end-systolic
period (t = 0.59–0.8 s).
CFD flow and velocity profiles in the cannula
showed good correlation (r > 0.94) with the profiles
measured by 4D-flow MRI (Figs. 6a and 6b). Near the
membrane insertion (Fig. 6c), the simulation produced
more conservative results with velocity magnitudes
well below values recorded in the MR measurements
(r = 0.76). Yet, peak values were elevated 27.9% in
the velocity computations compared to the MR scan.
The flow solution on a cross-section of the sym-
metric prototype from both the CFD simulation and
the 4D-flow MRI are displayed in Fig. 7. The pneu-
matic port, which was not centrally positioned
(Figs. 1b and 1e), led to the diaphragm deforming
asymmetrically as evidenced by the MRI data (Fig. 7a
right). At initial diastole (tID), CFD and MRI data
revealed comparable velocity distributions within the
cannula (0.916 vs. 0.922 m s21). The simplified mem-
brane deflection in the numerical setup resulted in early
axisymmetric vortex formation. In contrast, the actual
asymmetric deformation apparent in the MR scan led
to delayed vortex generation due to the rapid down-
ward motion of the membrane tip. At end-diastole
(tED) and at the start of systole (tSS), vortices with
similar flow features crystallized in both data sets, but
with velocities appearing qualitatively elevated in the
CFD computations. During mid-systole (tMS), the MR
scan again disclosed asymmetric membrane deforma-
tion, however, with comparable flow patterns evident
among CFD and MR results.
DISCUSSION
In this study, the development of the CoPulse
pump—a valveless pulsatile MCS device—was pro-
gressed from a concept to a functional prototype.
Previous numerical hemodynamic findings11 were val-
idated in vitro and further substantiated ex vivo, and
hemocompatible design feasibility was analyzed by
combining CFD and 4D-flow MRI.
Hemodynamic Evaluation
The hybrid in vitro test bench enabled testing of the
physical CoPulse pump, pneumatic driver, and control
system. The in silico results, which exhibited the
pump’s potential to normalize hemodynamics of vari-
ous HFpEF phenotypes,11 could be replicated with a
marginal difference in mean hemodynamic findings
(AoP, LAP, CO, PAP) of < 3.98% and close agree-
ment in LVP and LVV. These results confirmed that
the CoPulse pump may increase CO and reduce
LAP—effects that could be especially valuable for
HFpEF patients that are burdened by abnormally high
filling pressures and compromised CO.
The ex vivo isolated heart provided a physical model
of a heart in combination with the pump system to
validate the interaction between the pump and the
ventricle under controlled hemodynamic conditions.
The hemodynamics and PV loops displayed the same
trends and morphology as in silico and in vitro results.
CoPulse pump support increased CO and MAP when
FIGURE 5. Time evolution for dye washout in the symmetric
and the asymmetric design of the CoPulse pump. The virtual
dye injection experiment started with the systolic phase (t = 0–
0.4 s) where some of the tracer was expelled together with
blood, causing a drop in the dye concentration. In the
subsequent filling phase (t = 0.4–0.8 s), pure blood entered
the pump while the tracer concentration within the chamber
remained constant. This cycle recurred throughout the entire
pumping process, eventually resulting in a staggered
progression of dye washout.
FIGURE 6. Comparison of flow (a) and velocity profiles (b, c) among 4D-flow MRI and CFD for the symmetric design of the
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FIGURE 7. Comparison of CFD data (left) to 4D-flow MRI recording (right) for the symmetric design of the CoPulse pump.






the LAP was kept constant. In the case of constant
CO, the LAP was reduced. In both cases, the ESV was
not further reduced compared to the unsupported
condition since the CoPulse pump only fills while the
mitral valve is open. These results further confirmed
the CoPulse’s hemodynamic effect and suggest that
ventricles supported with the CoPulse pump may
mitigate the risk of suction events, which constitutes a
major obstacle for the treatment of HFpEF patients
with MCS devices.22
Under the implemented mode of operation of the
pump, volumetric efficiencies of 31–41% and pump
work efficiencies of about 68–85% were observed. The
volumetric efficiency can be interpreted as the per-
centage of SVpump that is converted into useful CO.
Part of the SVpump is absorbed by the LV which pri-
marily varies according to the systolic properties of the
heart. This highlights the requirement of a stiff ESPVR
for efficient functionality of the CoPulse pump. An-
other part of the SVpump is converted into pressure
within the LV, which is captured by the work efficiency
of the pump. The work efficiency provided a measure
of the total additional SW that is performed by the LV
and pump compared to the unsupported HFpEF
ventricle. Therefore, approximately 40% of the SVpump
is converted into CO while approximately 80% of the
pump work is retained as useful SW of the LV and
pump. The lowest volumetric and work efficiency was
observed for HFpEF II as it represents the phenotype
with the least stiff systolic properties and with rela-
tively less-stiff diastolic properties. This causes the LV
to absorb more energy during pump ejection and fill-
ing. Further studies are required to delineate the
specific systolic and diastolic cardiac properties that
optimally capitalize on the clinically relevant benefits
of the CoPulse pump.
In vitro and ex vivo results showed that CoPulse
support reduced SWLV in exchange for increased PELV
with nearly conserving the total PVALV—a measure of
the total mechanical energy consumption of the LV
during a cardiac cycle. A similar exploration on the
effect of synchronized MCS device support on LV
energetics was conducted also with a single cannula
pump, except in an chronic ovine model of dilated
heart failure15 and an acute healthy ovine model.16 The
study presented contrasting results that such a pump
would increase overall SWLV while still increasing CO
by augmenting the total SV. This discrepancy can be
attributed to the different modus operandi of pump
ejection/filling phasing employed. Landesberg et al.
fills the pump during isovolumetric relaxation, reduc-
ing the ESV and lowering the diastolic pressure in the
ventricle prior to the beginning of ventricular diastole.
This could result in an increased risk for suction events
and increases the work performed by the diseased LV.
By filling only during LV filling, the majority of the
work performed during pump filling is on the circula-
tory system instead of the LV while still providing
similar CO augmentation (22.516 vs. 14–31% in vitro
and 21 ± 9.3% ex vivo). Which modus operandi would
better promote chronic reversal of underlying hyper-
trophy that contributes toward certain HFpEF phe-
notypes is debatable and demands long-term studies.
Fluid Dynamic Evaluation
The fluid dynamic analysis disclosed an asymmetric
pump configuration with an offset tilted cannula to
provide the best trade-off among blood stagnation
prevention, blood washout performance, and low le-
vels of shear stresses. A similar design was previously
introduced for a 30 mL single port valveless counter-
pulsation device (Symphony, Abiomed Inc., MA,
USA) that was to be connected to the subclavian
artery.9 In a study combining CFD, particle image
velocimetry (PIV), and animal experiments, the au-
thors claimed the Symphony to be hemocompatible
with low risks for hemolysis or thrombus formation
and concluded the design to be adequate for human
implantation. Yet, the pump dimensions deviate from
those specified for the CoPulse pump and the narrow
anatomical constraints of the pericardial space could
impede implantability of the Symphony pump into the
LV apex due to its tangential cannula configuration
(h = 0).
To allow for good fit within the pericardial space
when implanted into the LV apex, the asymmetric
CoPulse pump incorporates a cannula attached at an
angle of h = 60. This configuration proved sufficient
to generate a persistent, unidirectional flow throughout
the entire pump cycle, thus significantly reducing blood
stagnation, and consequently, the risk for thrombus
formation in the vicinity of the membrane insertion.
However, the optimized asymmetric design revealed
elevated peak shear stresses at the housing and on the
membrane as compared to the symmetric design. The
latter observation coincided with the findings of Xu
et al.29 claiming the reduced potential for thrombus
deposition to generally be at the expense of elevated
risks for hemolysis or platelet activation. However,
levels of shear stresses within the asymmetric CoPulse
pump were significantly lower than those observed in
the Symphony device9 and remained well below the
threshold for platelet activation (50 Pa) or hemolysis
(150 Pa).
The duration for 95% dye washout (t95 = 2.66 s) as
well as the average blood residence time
(RT1 = 0.95 s) calculated for the asymmetric CoPulse
pump revealed slightly elevated values as compared to
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in- and outlet port (t95 = 2.47 s, RT1 = 0.893 s).
18
However, the latter study was conducted for a 73 mL
pump operated at 80 bpm, thus limiting direct com-
parison with the CoPulse pump (30 mL, 75 bpm). We
performed a sensitivity analysis that, along with the
publication of Xu et al.,29 indicated the elevated heart
rate and stroke volume in the adult pVAD to be in
favor of good washout as compared to the CoPulse
pump. Increasing the stroke volume of the CoPulse
pump to 35 mL already resulted in comparable dye
washout (t95 = 2.55 s) and superior blood residence
time (RT1 = 0.835 s) as compared to the adult pVAD.
This further demonstrates the feasibility of a single
cannula valveless design with comparable hemocom-
patibility features inherent to conventional pVADs
with separate in- and outflow cannula that are com-
monly implanted in HFrEF patients.
CFD-based methodologies, as presented in this
study, are widely accepted as a powerful tool for flow
inspection and hemocompatibility characterization
within VADs. However, the validation of such
numerical studies is of paramount importance to as-
sure reliable results. For this purpose, CFD data is
commonly compared against flow visualization exper-
iments.1 Within the frame of this study, 4D-flow MRI
was employed for CFD-validation. The recordings
revealed the membrane to deflect asymmetrically
mainly due to the offset pneumatic port. Despite the
idealized membrane motion implemented in the CFD
setup, the results showed a high level of agreement
among CFD and MRI data (r > 0.76), wherefore
validity of the CFD results was assumed.
LIMITATIONS
Although the developed models are fit for investi-
gating the acute effects of the pump, they do not
account for the influences of some physiological
adaptive mechanisms (e.g. neural, hormonal). Without
the establishment of an adequate large animal model of
HFpEF, the in-vivo evaluation for such a device is
challenging. The isolated heart model has previously
been used for evaluation of other MCS devices10 and is
particularly adapted for controlled hemodynamic and
visual investigations. The isolated hearts indicated
decreased diastolic compliance, a common character-
istic of HFpEF phenotypes, made evident by the steep
EDPVR found for all the porcine hearts; however,
ESPVR was flatter for some porcine hearts addition-
ally indicating reduced systolic function (Fig. 3b).
The hydraulic design of the CoPulse pump was
optimized at a typical operating point of 75 bpm and
under the assumption of a simplified membrane mo-
tion. Although the numerical simulation did not
accurately capture the actual membrane motion, CFD
data disclosed good agreement with 4D-flow MRI.
However, the impact of the actual asymmetric mem-
brane motion on the fluid dynamics within the pump
chamber remains to be studied under a broader range
of operating settings in order to assure favorable
hemocompatibility characteristics for all clinically rel-
evant conditions. For this purpose, fluid-structure-in-
teraction simulations are proposed to accurately
capture the realistic membrane motion by considering
the interaction of air, blood and diaphragm at relevant
operating conditions. To validate those in silico
hemocompatibility characteristics, in vitro and in-vivo
studies are to be conducted in order to claim appro-
priate pump hemocompatibility.
CONCLUSION
The in vitro hybrid mock circulatory loop and the
ex vivo isolated porcine heart model disclosed the
CoPulse pump to improve hemodynamics for specific
HFpEF phenotypes by lowering LAP and increasing
CO while potentially obviating the risk for suction
events. Further, hemocompatible design feasibility was
demonstrated, revealing moderate shear stresses with
comparable characteristics for pump washout and
blood residence time as previously reported for a
pVAD with two cannulas typically implanted in
HFrEF patients.18 This successful completion of the
early stage device development process supports the
further progression of the CoPulse pump.
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